Mission: To create new anti-inflammatory therapies that are highly effective, easy to use, and safer than existing options for  sight-threatening eye diseases. 

Progress: Designed lead candidate that is being advanced towards clinical development:

  • Is effective in multiple models of inflammatory disease
  • Distributes to the retina upon application of an eye drop

Recognizing the significant need for new, effective, safer treatment options for patients with debilitating inflammatory conditions, particularly in an aging population, Naegis was formed to create new, effective and safer treatment options for patients.  Naegis uses its expertise in a small molecule drug discovery to find and advance lead candidates that inhibit the production of key pro-inflammatory mediators in inflammatory disease.  While these mediators are involved in many diseases, the company has chosen to focus first on serious inflammatory eye conditions, including uveitis and diabetic macular edema.


We use cookies to improve our website. By continuing to use this website, you are giving consent to cookies being used. More details…